iBio, Inc.

Equities

IBIO

US4510337086

Pharmaceuticals

Delayed Nyse 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.06 USD +20.83% Intraday chart for iBio, Inc. +275.93% +196.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Premarket Gainers MT
Top Midday Gainers MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data MT
Transcript : IBio, Inc. - Special Call
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings MT
Top Premarket Gainers MT
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases CI
IBio, Inc. announced that it has received $14 million in funding CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka DJ
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc.. CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Top Midday Decliners MT
Top Premarket Decliners MT
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report DJ
IBio Board Approves 20-to-1 Reverse Split of Common Stock Effective Nov. 29; Shares Sink 11% After Hours MT
IBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
IBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx CI
North American Morning Briefing : Stock Futures, -2- DJ
IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
IBio Unit, Woodforest National Bank Amend Credit Agreement MT
IBio, Inc. Reports Triple Milestone in Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development CI
IBio, Inc. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC CI
IBio Names Martin Brenner Chief Executive; Felipe Duran Appointed as Finance Chief MT
IBio, Inc. Announces the Appointment of Felipe Duran as Chief Financial Officer CI
Chart iBio, Inc.
More charts
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock iBio, Inc. - Nyse
  4. News iBio, Inc.
  5. iBio : Earnings Flash (IBIO) IBIO Reports Q3 Revenue $765,000, vs. Street Est of $0.8M